Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates?
Key takeaways
- Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates?
- The proposal would make the program permanent starting in 2029 and introduce stricter requirements around fixed-combination lifecycle strategies.
- The application received Priority Review status, with the FDA assigning a PDUFA target action date of September 30, 2026.
Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates? Laiba Immad Tue, June 30, 2026 at 8:07 PM GMT+7 2 min read BMY We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company (NYSE:BMY) is one of the best low-priced pharma stocks on this list.
The Fly reported on June 15 that RBC Capital analyst Trung Huynh noted that the proposed changes to the Medicare Drug Price Negotiation Program could introduce potential risks for companies, including Bristol-Myers Squibb Company (NYSE:BMY) and several others. The proposal would make the program permanent starting in 2029 and introduce stricter requirements around fixed-combination lifecycle strategies. However, the analyst highlighted that legal challenges, regulatory exemptions, and diversified product portfolios may reduce the overall impact on these companies.
In a separate regulatory update on June 1, BMY announced that the FDA accepted its supplemental New Drug Application for Camzyos as a potential treatment for adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The application received Priority Review status, with the FDA assigning a PDUFA target action date of September 30, 2026. If approved, Camzyos would become the first cardiac myosin inhibitor available for adolescent patients with oHCM. The therapy is currently approved for adults with symptomatic NYHA class II-III oHCM to improve symptoms and functional capacity, with use reported among thousands of healthcare providers and patients across the U.S.